Management and 5-Year Survival of BRCA1 -Associated Breast Cancer Patients

Abstract

Aim: The aim of this study is to estimate survival of breast cancer patients associated with BRCA1 mutation in Lithuanian population. Materials & methods: We studied the 5-year survival rates of familial breast cancer patients from unrelated families who had an aggregation of at least two or three breast cancers only; and a group comprising of consecutive, newly diagnosed patients unselected for age, sex or family history. The treatment of patients was similar, as per National protocols, for the treatment of breast cancer cases independent of mutation status. Results: The 5-year survival of familial and non-familial breast cancer patients BRCA1 founder mutation carriers is statistically similar to patients the mutation non-carriers: 90.00 and 89.19%; 76.92 and 86.19% respectively (p = 0.7730). Conclusion: The 5-year survival rates for breast cancer patients are not dependent on their BRCA1 mutation carrier status when identical management and treatment is received.